CORRECTION: Sequenom's Q3 Revenues Drop 20 Percent as Net Loss Swells 43 Percent

Sequenom also said that it amended its license with Isis Innovation for IP underlying its SEQureDx Down syndrome test, which the firm continues to develop following an investigation into mishandled R&D test data and results.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories